Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today ...

Innovent Biologics, the first Chinese firm to gain approval for a GLP-1 weight loss and diabetes drug, has partnered with JD Health for online distribution.

When it comes to medications like Ozempic, the focus is usually on weight loss. However, a recent study from SSM Health St.